<DOC>
	<DOCNO>NCT03054350</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled , dose-finding study ass efficacy , safety , tolerability , PK , PD orally administer vadadustat Japanese subject anemia secondary DD-CKD .</brief_summary>
	<brief_title>Dose-Finding Study Vadadustat Japanese Subjects With Anemia Secondary Dialysis-Dependent Chronic Kidney Disease ( DD-CKD )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Male female Japanese subject â‰¥20 year age Receiving chronic maintenance hemodialysis endstage kidney disease Hb &lt; 10.0 g/dL Anemia due cause CKD presence active bleeding recent blood loss Sickle cell disease , myelodysplastic syndrome , bone marrow fibrosis , hematologic malignancy , myeloma , hemolytic anemia , thalassemia , pure red cell aplasia Red blood cell transfusion within 4 week prior screen Anticipated recover adequate kidney function longer require hemodialysis study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>kidney</keyword>
	<keyword>dialysis-dependent chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>DD-CKD</keyword>
	<keyword>renal</keyword>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>Japan</keyword>
	<keyword>Japanese</keyword>
</DOC>